Allergan Announces FDA Approval Of JUVÉDERM VOLBELLA XC - Quick Facts

(RTTNews) - Allergan plc (AGN) announced it has received approval from the U.S. FDA to market JUVÉDERM VOLBELLA XC, for use in the lips for lip augmentation and for correction of perioral rhytids, commonly referred to as perioral lines, in adults over the age of 21. JUVÉDERM VOLBELLA XC will be available to patients in October 2016.

The company said the safety and effectiveness of JUVÉDERM VOLBELLA XC has been demonstrated in several clinical trials including the U.S. pivotal study where 168 subjects were treated with the drug.

JUVÉDERM VOLBELLA XC was first approved in Europe in 2011. Currently, it is distributed in more than 70 countries.